Phaseline

Companies › Sound Biopharmaceuticals

Sound Biopharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FTL008.16–Phase 1Solid TumorsNov 2026
FTL001–Phase 1Solid TumorMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06410131FTL008.16Phase 1Solid TumorsOncologyNov 2026
NCT06410092FTL001Phase 1Solid TumorOncologyMar 2027

From the company's SEC filings

Cash of 655m CNY on 2025-12-31; operating cash flow positive

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.